Mission Statement: Evidence-based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research ...

Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – ...

Am J Health Syst Pharm. 2011;68(15):1419-1425. The short duration of activity of naloxone when the drug is administered as an i.v. bolus may limit its effectiveness for the management of OIP ...

Unlike allergen-induced conditions, CSU is driven by immune system responses and is typically managed symptomatically with antihistamines, antipruritic, and anti-inflammatory treatments. Remibrutinib ...

Preclinical and clinical data indicate seladelpar has anticholestatic, anti-inflammatory, antipruritic, and antifibrotic effects. Seladelpar has potential to help meet the current unmet need of ...